{"data":{"ticker":"AZN","slug":"astrazeneca","name":"AstraZeneca","exchange":"NASDAQ","sector":"Healthcare","headquarters":"Cambridge, United Kingdom","ceo":"Pascal Claude Roland Soriot D.V.M.","employees":96100,"website":"https://www.astrazeneca.com","founded":"1999","layers":[{"slug":"ai-healthcare","name":"AI Healthcare"}],"exposure":{"score":8,"tier":"Peripheral","rationale":"AstraZeneca sells pharmaceuticals and uses AI in drug discovery, trial design, and precision medicine to improve R&D productivity. AI is a tool that may raise pipeline odds over time, but value is driven by drug launches and patents, not AI demand."},"quote":{"price":186.43,"change24hPct":-0.22,"change7dPct":-0.12,"change30dPct":17.41,"change1yPct":11.36,"high52w":208.62,"low52w":155.62,"marketCap":289137557504,"peRatio":26.37,"eps":7.07,"volume24h":515947635},"nextEarningsDate":"2026-10-30","summary":"AstraZeneca is a global pharmaceutical company. It makes money selling prescription medicines across oncology, cardiovascular, and rare diseases, backed by a research pipeline that feeds new drug launches.","explainer":["AstraZeneca is a global pharmaceutical company. It makes money selling prescription medicines across oncology, cardiovascular, and rare diseases, backed by a research pipeline that feeds new drug launches.","AI works inside its R&D machine: an AI drug discovery platform helps identify candidates, clinical trial AI improves study design, precision medicine AI matches treatments to patients, and biomarker analytics find the biological signals that guide development.","Founded in 1999 and headquartered in Cambridge, United Kingdom, AstraZeneca trades on the NASDAQ and employs about 96,100 people."],"buildoutRole":"AstraZeneca sits in the AI Healthcare layer of the buildout as an adopter rather than a supplier. AI in discovery, trial design, and precision medicine may raise pipeline odds over time, which is why it invests. Value is still driven by drug launches and patents rather than AI demand, so Supercycle scores its AI exposure at 8 out of 100.","faq":[{"q":"What does AstraZeneca do?","a":"AstraZeneca develops and sells prescription medicines, with strength in oncology, cardiovascular, and rare diseases. Its revenue comes from drugs sold globally, supported by a research pipeline of new therapies."},{"q":"How is AstraZeneca exposed to AI?","a":"Peripherally. AI supports drug discovery, trial design, and precision medicine as a productivity tool that may raise pipeline odds, while value follows launches and patents. Supercycle gives it an AI Exposure Score of 8 out of 100."},{"q":"What are AstraZeneca's main AI capabilities?","a":"An AI drug discovery platform, clinical trial AI design tools, precision medicine AI that matches treatments to patients, and biomarker AI analytics that guide drug development decisions."},{"q":"Where is AstraZeneca headquartered and who leads it?","a":"AstraZeneca is headquartered in Cambridge, United Kingdom, and led by CEO Pascal Soriot. The company was founded in 1999, employs about 96,100 people, and its shares trade on the NASDAQ."},{"q":"Is AZN a pure play AI stock?","a":"No. AstraZeneca is a pharmaceutical company that applies AI inside research and development. With an AI Exposure Score of 8 out of 100, it sits near the low end of the AI Exposure leaderboard."}],"history1y":[{"date":"2026-09-28","close":166.15},{"date":"2026-09-29","close":164.21},{"date":"2026-09-30","close":161.47},{"date":"2026-10-01","close":157.7},{"date":"2026-10-02","close":156.9},{"date":"2026-10-05","close":156.53},{"date":"2026-10-06","close":158.61},{"date":"2026-10-07","close":160.12},{"date":"2026-10-08","close":158.78},{"date":"2026-10-09","close":159.2},{"date":"2026-10-12","close":158.33},{"date":"2026-10-13","close":155.82},{"date":"2026-10-14","close":162.03},{"date":"2026-10-15","close":166.68},{"date":"2026-10-16","close":165.41},{"date":"2026-10-19","close":163.95},{"date":"2026-10-20","close":168.82},{"date":"2026-10-21","close":168.45},{"date":"2026-10-22","close":172.57},{"date":"2026-10-23","close":171.49},{"date":"2026-10-26","close":172.06},{"date":"2026-10-27","close":170.08},{"date":"2026-10-28","close":169.51},{"date":"2026-10-29","close":174.4},{"date":"2026-10-30","close":186.65},{"date":"2026-11-02","close":186.58},{"date":"2026-11-03","close":183.88},{"date":"2026-11-04","close":189.01},{"date":"2026-11-05","close":186.85},{"date":"2026-11-06","close":186.43}],"incomeStatements":[{"ticker":"AZN","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","revenue":58739000000,"cost_of_revenue":10633000000,"gross_profit":48106000000,"operating_expense":0,"operating_income":13327000000,"net_income":10225000000,"earnings_per_share":6.54,"earnings_per_share_diluted":6.54,"research_and_development":14232000000,"selling_general_and_administrative_expenses":20774000000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"AZN","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","revenue":54073000000,"cost_of_revenue":10207000000,"gross_profit":43866000000,"operating_expense":0,"operating_income":10251000000,"net_income":7035000000,"earnings_per_share":4.5,"earnings_per_share_diluted":4.5,"research_and_development":13583000000,"selling_general_and_administrative_expenses":20224000000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"AZN","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","revenue":45811000000,"cost_of_revenue":8268000000,"gross_profit":37543000000,"operating_expense":0,"operating_income":8722000000,"net_income":5955000000,"earnings_per_share":3.81,"earnings_per_share_diluted":3.81,"research_and_development":10935000000,"selling_general_and_administrative_expenses":18222000000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"AZN","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","revenue":44351000000,"cost_of_revenue":12391000000,"gross_profit":31960000000,"operating_expense":0,"operating_income":4512000000,"net_income":3288000000,"earnings_per_share":2.11,"earnings_per_share_diluted":2.11,"research_and_development":9762000000,"selling_general_and_administrative_expenses":17984000000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0}],"balanceSheets":[{"ticker":"AZN","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","total_assets":114074000000,"current_assets":28723000000,"cash_and_equivalents":5711000000,"total_liabilities":65355000000,"current_liabilities":30617000000,"total_debt":29149000000,"shareholders_equity":48667000000,"retained_earnings":10972000000},{"ticker":"AZN","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","total_assets":104035000000,"current_assets":25827000000,"cash_and_equivalents":5488000000,"total_liabilities":63164000000,"current_liabilities":27866000000,"total_debt":30114000000,"shareholders_equity":40786000000,"retained_earnings":3160000000},{"ticker":"AZN","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","total_assets":101119000000,"current_assets":25054000000,"cash_and_equivalents":5840000000,"total_liabilities":61953000000,"current_liabilities":30542000000,"total_debt":28407000000,"shareholders_equity":39143000000,"retained_earnings":1502000000},{"ticker":"AZN","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","total_assets":96483000000,"current_assets":22593000000,"cash_and_equivalents":6166000000,"total_liabilities":59425000000,"current_liabilities":26293000000,"total_debt":29143000000,"shareholders_equity":37037000000,"retained_earnings":-574000000}],"holders13f":[],"news":[{"title":"European Stocks Close Mostly Lower in Thursday Trading as Investors Parse Earnings Reports, US Elections, Rising Oil Prices","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/european-stocks-close-mostly-lower-165559834.html?.tsrc=rss","date":"2026-11-05"},{"title":"RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report","source":null,"url":"https://stocktwits.com/news-articles/markets/equity/rytm-stock-clocks-best-day-in-nearly-16-months-on-astra-zeneca-10-b-bid-report/cNGLYtyR9ER?.tsrc=rss","date":"2026-11-04"},{"title":"Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/rhythm-pharmaceuticals-stock-surges-28-215311611.html?.tsrc=rss","date":"2026-11-04"},{"title":"Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026","source":null,"url":"https://finance.yahoo.com/healthcare/articles/summit-therapeutics-reports-financial-results-213600354.html?.tsrc=rss","date":"2026-11-04"},{"title":"Antibody-Drug Conjugates (ADC) Market Size, Share, Trends, and Global Forecast to 2036 | Market Set to Reach $74.15 Billion at 13.5% CAGR as Next-Generation ADCs and Asia-Pacific Drive Growth","source":null,"url":"https://finance.yahoo.com/healthcare/articles/antibody-drug-conjugates-adc-market-161600869.html?.tsrc=rss","date":"2026-11-05"},{"title":"Innate Pharma Q3 Earnings Call Highlights","source":null,"url":"https://www.marketbeat.com/instant-alerts/transcript-innate-pharma-q3-earnings-call-highlights-2026-11-05/?utm_source=yahoofinance&utm_medium=yahoofinance&.tsrc=rss","date":"2026-11-05"},{"title":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update","source":null,"url":"https://finance.yahoo.com/healthcare/articles/innate-pharma-reports-third-quarter-060000799.html?.tsrc=rss","date":"2026-11-05"},{"title":"Novo hires new CFO as Wegovy pill hits more markets","source":null,"url":"https://www.cfodive.com/news/novo-hires-new-cfo-wegovy-pill-hits-new-markets-compensation/873774/?.tsrc=rss","date":"2026-11-04"}]},"meta":{"version":"v1","asOf":"2026-11-06","builtAt":"2026-11-08T15:24:45.406Z","tier":"free","source":"https://supercyclehq.com/stock/astrazeneca","disclaimer":"Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.","license":"Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."},"links":{"self":"https://supercyclehq.com/api/v1/stocks/AZN","html":"https://supercyclehq.com/stock/astrazeneca","md":"https://supercyclehq.com/stock/astrazeneca.md","docs":"https://supercyclehq.com/api/v1/openapi.json"}}